Abdullah M. Al-Osaimi
( Email )
Assistant Professor
Department of Medicine, Gastroenterology
PO Box 800708
Charlottesville, VA 22908
Phone:434-924-0316
Education and Experiences:
(MBBS) King Saud University
Interests:
Liver transplantation, HCC, fatty liver disease, viral hepatitis, and cholestatic liver disease
Selected Projects:
Comparison of PEG-Intron 1.5 mcg/kg/wk plus...
MD-DHCE 12510 FBX 104114: A Double-blind, Randomized, Placebo-controlled, Multi-center PhaseII Parallel Dose Ranging Study of GI1262570 in Chronic Hepatitis C Patients
Study to Evaluate the Safety & Efficacy of Eltrombopag
11729 The A2ALL LADR Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C
MD-DHCR MR Spectroscopy of the Liver in Correlation with Histology in NASH Patients
MD-DHCR A Double-blind, Randomized, Placebo Controlled, Parallel Group Study of Rimonobant 20mg Daily fo rthe Treatment of Type 2 Diabetic Patients with Nonalcoholic Steatohepatitis (NASH)
Parallel Group Study of Rimonobant 20 mg Daily for the Treatment of Non-diabetic Patients
Randomized, Placebo-Controlled, Multi-Center Study to Assess Efficacy & Safety of Eltrombopag
MD-DHCR ENABLE 1 Randomized, Placebo-controlled, Multi Center Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects with Hepatitis C Virus HCV Infection who are Otherwise Eligible to Initiate Antiviral Therapy
A Phase 3, Safety & Efficacy Study of Boceprevir
MD-DHCE A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate teh Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults with Non-Alcoholic Steatohepatitis (NASH)
A Phase 3 Safety & Efficacy Study of Boceprevir
|
RSS Feed